Ladiratuzumab (hLIV22) is a humanized monoclonal antibody specifically targeting the zinc transporter LIV-1/ZIP6. This antibody is chemically linked to monomethyl auristatin E (MMAE) through a cleavable dipeptide linker, forming the antibody-drug conjugate (ADC) known as Ladiratuzumab vedotin. Designed for precision in oncological therapies, Ladiratuzumab vedotin binds selectively to the LIV-1 protein, which is frequently overexpressed on the surface of various tumor cells. Upon binding, the conjugate is internalized via receptor-mediated endocytosis, facilitating the intracellular release of MMAE. This potent cytotoxic agent acts by disrupting microtubule polymerization, leading to cell cycle arrest and apoptosis of the tumor cells. Additionally, Ladiratuzumab vedotin exhibits a bystander effect, where the cytotoxic agent can diffuse and eliminate neighboring tumor cells, enhancing its therapeutic efficacy. This ADC is particularly relevant in research focused on solid tumors, including metastatic triple-negative breast cancer (mTNBC), where conventional treatments often fall short.
Ladiratuzumab (hLIV22) is a humanized monoclonal antibody specifically targeting the zinc transporter LIV-1/ZIP6. This antibody is chemically linked to monomethyl auristatin E (MMAE) through a cleavable dipeptide linker, forming the antibody-drug conjugate (ADC) known as Ladiratuzumab vedotin. Designed for precision in oncological therapies, Ladiratuzumab vedotin binds selectively to the LIV-1 protein, which is frequently overexpressed on the surface of various tumor cells. Upon binding, the conjugate is internalized via receptor-mediated endocytosis, facilitating the intracellular release of MMAE. This potent cytotoxic agent acts by disrupting microtubule polymerization, leading to cell cycle arrest and apoptosis of the tumor cells. Additionally, Ladiratuzumab vedotin exhibits a bystander effect, where the cytotoxic agent can diffuse and eliminate neighboring tumor cells, enhancing its therapeutic efficacy. This ADC is particularly relevant in research focused on solid tumors, including metastatic triple-negative breast cancer (mTNBC), where conventional treatments often fall short.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
